ACAD Stock Analysis: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$29.50
0.46 (1.58%)
▲
5d:
+4.46%
30d:
+18.81%
90d:
+38.37%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 20, 2026 at $29.31 · last confirmed Aug 20, 2026
Strength: 5.6/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ACAD shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ACAD shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.26
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.86
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $29.50, which is considered extended relative to its 30-day fair value range of $25.28 to $28.92. From a valuation perspective, the stock is trading at a premium (Forward PE: 33.2) compared to its historical average (27.9). At these levels, the market is pricing in 6.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ACAD is in a strong uptrend. Immediate support is located at $27.90, while resistance sits at $30.96.
Market Sentiment: ACAD scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.85 (+14.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ACAD is in a strong uptrend. Immediate support is located at $27.90, while resistance sits at $30.96.
Market Sentiment: ACAD scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $33.85 (+14.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$25.28 -
$28.92
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
25.2%
Protect Your Profits
Holding ACAD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($33.85)
- NEUTRAL: Trading at premium valuation - market expects 6.0% growth which is achievable
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$25.28 -
$28.92
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$27.90
Resistance Level
$30.96
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.20
Wall Street Target
$33.85
(+14.7%)
Revenue Growth (YoY)
16.4%
Earnings Growth (YoY)
13.3%
Profit Margin
33.4%
Valuation Premium vs History
+6.0% premium
PE vs Historical
33.2 vs 27.9
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.0%
(market-implied from PE analysis)
1-Year Target
$31.27
(+6%)
2-Year Target
$33.15
(+12%)
3-Year Target
$35.13
(+19%)
3-Yr Target (if PE normalizes)
(PE: 33→28)
PE COMPRESSION
$29.53
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.2, Growth: 48.4%)
$96.50
(+227%)
Base:
(SPY PE: 20.1, Growth: 48.4%)
$58.34
(+98%)
Bear:
(PE: 17.1, Growth: 48.4%)
$49.59
(+68%)
📈
Valuation based on Current Earnings
Trailing PE: 13.57 | Current EPS (TTM): $2.14
Bull Case
$15.97
(-46%)
Analyst growth -50.0%, PE expands to 14.9
Base Case
$14.52
(-51%)
Market implied -50.0%, PE stable at 13.6
Bear Case
$19.75
(-33%)
Severe decline -20.0%, PE contracts to 11.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 12:38 PM ET
Data refreshes hourly during market hours. Next update: 1:38 PM
Data refreshes hourly during market hours. Next update: 1:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
James Kihara
SELL
1030 shares
2026-04-07
Mark C Schneyer
SELL
2709 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
TNYA
Tenaya Therapeutics Inc |
STRONG BUY
9 analysts |
$3 | 69 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 37 SELL |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
